What is Zyban (Bupropion)
Zyban is a Glaxo-Wellcome product conceived to treat nicotine addiction and to determine smoke quitting. Zyban doesn’t replace nicotine suppliers, cigarettes that is, but it works by decreasing nicotine cravings directly where they are formed, in the brain. Even though approved in the U.S., Zyban still hasn't obtained the grant of U.K. medical authority.
Patient information
Zyban is a Glaxo-Wellcome product conceived to treat nicotine
addiction and to determine smoke quitting. Zyban does not replace nicotine suppliers, cigarettes that is, but it works by decreasing nicotine
cravings directly where they are formed, in the brain. Even though
approved in the U.S., Zyban still has not obtained the grant of
U.K.
medical authority. However, the drug could shortly become one of
medicine’s greatest breakthroughs, considering it cures one of 21st
century’s top mortality causes.
Zyban’s active ingredient is not new on the pharmaceutical
market.
Bupropion Hydrochloride used to be known as Wellbutrin,
a popular
anti-depressant. Bupropion acts by inhibiting, even though weakly,
neuronal release of serotonin, dopamine and norepinephrine.
Directions of using Zyban:
Zyban is available in 150 mg tablets. Patients are recommended not to exceed a two tablet a day ratio, more than 300 mg of Zyban daily that is. In the first three days a dose of 150mg is advisable. The increase occurs, then, gradually up to 300mg.
Smokers are indicate to begin therapy with Zyban while still smoking and first results are expected within approximately 14 days since taking the first tablet. Therapy normally lasts for 7 to 12 weeks, as patients may respond differently to treatment. Some may experience significantly reduced nicotine cravings within the first 7 weeks and have all the chances to quit by the 12th week. Others may not feel any benefit by that time and should finish Zyban therapy.
Zyban's Side-effects:
During clinical trials, more than 2% the observed patients taking Zyban experienced dry mouth, sleep disorders, dizziness, irritation, arthralgia and pruritis. Uncommon reported adverse reactions, however, included disturbed intestinal traffic, abdominal pain, anorexia, rhinitis, irascibility, taste perversion, light head, pharygitis and others.
Contraindications to Zyban:
Studies developed in vitro have revealed possible interactions between Zyban and orphenadrine and cyclophosphamide containing drugs. Bupropion’s action may be annulled by other drugs containing cimetidine, while it may reduce the effectiveness of carbamazepine, phenytoin and phenobarbitol. Zyban is not recommended to patients taking Wellbutrin, antidepressant containing Bupropion, as effects may be increased.
Zyban is not recommended to patients currently or formerly suffering from bulimia or anorexia or to those taking MAOIs or those allergic to any of its ingredients. MAOI’s consumers are advised to take a 14 day break from their current treatment before starting to take Zyban.